...reuptake inhibitors to treat CNS disorders associated with anxiety, mood and stress-related disorders. BC Staff sutimlimab (BIVV009, tnt009) Sanofi Complement...

...to SEK135.70 on Monday. Sanofi and Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam...

...North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009...
...shareholders will receive $400 million up front and are eligible for $425 million in milestones. TNT009...
...TNT009 could "move quickly into a registrational trial." In the Phase Ib trial, Bioverativ said TNT009...

...exclude True North's undisclosed cash. Triggers for the milestones are undisclosed. True North’s lead asset, TNT009...
...to treat cold agglutinin disease (CAD). On a conference call, Bioverativ CEO John Cox said TNT009...
...it spun out from Biogen Inc. (NASDAQ:BIIB) in February (see BioCentury, Feb. 10, 2017) . TNT009...

...North Therapeutics Inc. (South San Francisco, Calif.). The deal gives Bioverativ rights to True North's TNT009...
...shareholders will receive $400 million up front and are eligible for $425 million in milestones. TNT009...
...TNT009 could "move quickly into a registrational trial." In the Phase Ib study, Bioverativ said TNT009...

...True North Therapeutics Inc. ’s first clinical data for lead molecule TNT009 convinced new investor HBM...
...meeting in Copenhagen showing that four of five cold agglutinin disease (CAD) patients treated with TNT009...
...of hemoglobin increase convinced HBM to back True North. He added that the firm expects TNT009...

...Perceptive Advisors. New investor Franklin Templeton Investments and undisclosed existing investors also participated. The company's TNT009...
...North announced interim Phase Ib data that showed three of five CAD patients treated with TNT009...
...meeting in Copenhagen. CEO Nancy Stagliano said the new round will support further development of TNT009...

...showed that a single dose of 10 mg/kg IV TNT009 followed by 60 mg/kg IV TNT009...
...patient program and re-exposure to TNT009 again led to remission in each of those patients. TNT009...
...is evaluating a single dose of 10 mg/kg IV TNT009 followed by 60 mg/kg IV TNT009...

...CAD, adding that the disease has a prevalence of about 20 per million. True North’s TNT009...

...and Baxalta Ventures. This month, True North plans to begin Phase Ib testing of its TNT009...
...to treat cold agglutinin disease (CAD). "There's always been a strong scientific rationale for why TNT009...